Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclosporine and inflammatory bowel disease: buying time.

Literature DB >> 9705599

Cyclosporine and inflammatory bowel disease: buying time.

Abstract

Cyclosporine is an effective drug in acute exacerbations of corticosteroid resistant ulcerative colitis, but its efficacy to maintain disease remission is not clear. Cyclosporine may not be as effective in Crohn's disease. However, being a rapidly acting immunosuppressant, cyclosporine may be a valuable therapeutic option in the short-term to treat corticosteroid resistant Crohn's disease and ulcerative colitis.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1998 PMID： 9705599 PMCID： PMC1781845 DOI： 10.1080/09629359891054

Source DB: PubMed Journal: Mediators Inflamm ISSN： 0962-9351 Impact factor: 4.711

23 in total

1. Cyclosporin A can switch the immune response induced by antigen from a humoral to a cell-mediated mode.

Authors: P A Bretscher; C Havele
Journal: Eur J Immunol Date: 1992-02 Impact factor: 5.532

2. Cyclosporine therapy in inflammatory bowel disease: open-label experience.

Authors: S Lichtiger
Journal: Mt Sinai J Med Date: 1990-10

3. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease.

Authors: J Brynskov; L Freund; S Nørby Rasmussen; K Lauritsen; O Schaffalitzky de Muckadell; C N Williams; A S MacDonald; R Tanton; F Molina; M C Campanini
Journal: Scand J Gastroenterol Date: 1991-07 Impact factor: 2.423

4. Cyclosporin for severe ulcerative colitis: a user's guide.

Authors: A Kornbluth; D H Present; S Lichtiger; S Hanauer
Journal: Am J Gastroenterol Date: 1997-09 Impact factor: 10.864

5. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

Authors: G Feutren; M J Mihatsch
Journal: N Engl J Med Date: 1992-06-18 Impact factor: 91.245

10. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors: D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal: Eur J Immunol Date: 1981-08 Impact factor: 5.532

Cyclosporine and inflammatory bowel disease: buying time.

1. Cyclosporin A can switch the immune response induced by antigen from a humoral to a cell-mediated mode.

2. Cyclosporine therapy in inflammatory bowel disease: open-label experience.

3. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease.

4. Cyclosporin for severe ulcerative colitis: a user's guide.

5. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

6. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

7. Effect of oral cyclosporin on renal function in Crohn's disease.

8. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease.

9. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A.

10. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.